StockData
BioAtla, Inc. logo

BioAtla, Inc. (BCAB) stock

BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$1.31−0.05 (-3.68%)

Close on Oct 19, 2026Market cap $2.18MP/E –Yield –

BioAtla net income

Net income is the profit left for shareholders after every expense, interest and tax.

BioAtla's net income for the twelve months ending Jun 30, 2026 was -$31.45M. For fiscal 2025 it was -$59.61M. The highest annual figure on record is -$29.86M in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.61M–
FY2024Dec 31, 2024-$69.78M–
FY2023Dec 31, 2023-$123.46M–
FY2022Dec 31, 2022-$106.48M–
FY2021Dec 31, 2021-$95.40M–
FY2020Dec 31, 2020-$35.85M–
FY2019Dec 31, 2019-$29.86M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$452.00K–
Q1 FY2026Mar 31, 2026-$6.34M–
Q4 FY2025Dec 31, 2025-$9.78M–
Q3 FY2025Sep 30, 2025-$15.78M–
Q2 FY2025Jun 30, 2025-$18.71M–
Q1 FY2025Mar 31, 2025-$15.33M–
Q4 FY2024Dec 31, 2024-$14.88M–
Q3 FY2024Sep 30, 2024-$10.59M–
Q2 FY2024Jun 30, 2024-$21.07M–
Q1 FY2024Mar 31, 2024-$23.23M–
Q4 FY2023Dec 31, 2023-$26.93M–
Q3 FY2023Sep 30, 2023-$33.33M–
Q2 FY2023Jun 30, 2023-$35.75M–
Q1 FY2023Mar 31, 2023-$27.46M–
Q4 FY2022Dec 31, 2022-$27.54M–
Q3 FY2022Sep 30, 2022-$25.78M–
Q2 FY2022Jun 30, 2022-$28.91M–
Q1 FY2022Mar 31, 2022-$24.25M–
Q4 FY2021Dec 31, 2021-$23.39M–
Q3 FY2021Sep 30, 2021-$22.93M–
Q2 FY2021Jun 30, 2021-$30.38M–
Q1 FY2021Mar 31, 2021-$18.70M–
Q4 FY2020Dec 31, 2020-$16.40M–
Q3 FY2020Sep 30, 2020-$11.63M–
Q2 FY2020Jun 30, 2020-$6.22M–
Q1 FY2020Mar 31, 2020-$1.60M–

More BioAtla figures

See a number that looks wrong?